1. Short title This Act may be cited as the Prescription for American Drug Independence Act of 2020 . 2. National Academies strategies To increase domestic manufacturing of critical drugs (a) In general Not later than 14 days after the date of enactment of this Act, the Secretary of Health and Human Services shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the National Academies ) under which, not later than 90 days after the date of entering into the agreement, the National Academies will— (1) establish a committee of experts who are knowledgeable about drug supply issues, including— (A) sourcing and production of critical drugs; (B) sourcing and production of active pharmaceutical ingredients in critical drugs; (C) the raw materials and other components for critical drugs; and (D) the public health and national security implications of the current supply chain for critical drugs; (2) convene a public symposium to— (A) analyze the impact of United States dependence on the foreign manufacturing of critical drugs on patient access and care, including in hospitals and intensive care units; and (B) recommend strategies to end United States dependence on foreign manufacturing to ensure the United States has a diverse and vital supply chain for critical drugs to protect the Nation from natural or hostile occurrences; and (3) submit a report on the symposium’s proceedings to the Congress and publish a summary of such proceedings on the public website of the National Academies. (b) Symposium In carrying out the agreement under subsection (a), the National Academies shall consult with— (1) the Department of Health and Human Services, the Department of Homeland Security, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate